
GENOMMA LAB INVESTOR DAY


NOVEMBER 3, 2016

Genoma Lab




Safe Harbor

This presentation may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.





Today's Presenters



Antonio Zamora



CFO

- Joined Dec 2015

Prior Experience:

- CCO Cydsa
- CFO Grupo LALA
- Strat. & Financial Planning PEPSICO
- McKinsey & Co

Marco Sparvieri





EVP SALES

- Joined April 2014

Prior Experience:

- EVP Sales P&G+20 years of
 - experience in consumer goods







Genomma Lab's Key Imperatives

Balanced geographic reach / International expansion

Shareholder value creation

Sustainable business model & enduring brands



Core Competencies

Before



Demand generation



Demand generation

Developing online



Talent

Talent +



POS execution

Better POS execution




Mexico: sell-in International: sellout, EBITDA, FCF Sell-out, EBITDA, FCF



Growth

Sustainable growth and brands



Future

Demand generation

Win online

Continue attracting global talent ++


Best POS execution


EBITDA, FCF and ROIC

Sustainable growth and brands



Agenda





LAB Highlights: Then and Now


Brand Equity Commercial Strategy Innovation

Financial Results and Outlook



Growth Achieved in OTC and PC Since 2010


Sales by Category






Genomma

Significant Geographic Diversification










ab.

Genomma

Growth Fueled by Organic Brands and Strategic Acquisitions






Genomma

New Management Focused on Generating Cashflow


Consolidated Cash Conversion Cycle in Days








Agenda






LAB Highlights: Then and Now

Brand Equity Commercial Strategy Innovation

Financial Results and Outlook



Sell-in Converging with Sell-out: Successful Destocking Process






Sell-in & sell-out converging



True Demand Supported by the Strength of our Brands

Actions taken to offset significant media inflation:

- **Reduction of 60% in GRP's vs YAGO**
- **Budget reallocated to optimize advertising expense**



*Real terms: adjusted by inflation. Sell-out affected by fill-rate. Base 100: 1Q14



Sell-out*


GRPs

2016



Agenda






LAB Highlights: Then and Now

Brand Equity Commercial Strategy Innovation

Financial Results and Outlook



LAB Participates in Attractive and **Growing Business Segments**



- **Sizable markets**
- brands




Growth potential Latin America **U.S. Hispanic market**

Well-recognized leading



Genomma is a Leading OTC Player within its Markets

Top Two Countries



Significant Growth Opportunity






Highly Fragmented

Increased Penetration of Core Brands

Revenue Mix in Mexico



~ 95% of sales in our international operations come from core brands.




Better product \bullet rotation in the POS

Higher profitability ulletthan non-core brands



Agenda





LAB Highlights: Then and Now

Brand Equity Commercial Strategy Innovation

Financial Results and Outlook



Our Path to Developing Megabrands

Two Megabrands > US \$100 million Product Line Extensions





Our Focus on Power Brands Drives Category Growth



Cold & Cough

Anti-acne



Skin Care





21




Antimycotics

Hair Care



Genomma's DNA: Disruptive Marketing Strategies to Grow Brands







"100 Secrets"

Home-made "recipes" of Pomada de la Campana

Mix with natural ingredients to obtain different skin benefits (exfoliation, hydration, etc.).



Teatrical: Developing a Power Brand









Tentres

Expansion into body

2016

Tealmon

- Design relaunch
- "Anti-wrinkle" innovation
- New sizes

\$164




Acquired Brand Transformed into a Local Power Brand



Source: Cid Latina – CT D01A OTC.




Local Power Brand



Source: Cid Latina – N02B + M01A.


Strengthening our Product Portfolio **Category Mix in the U.S.**



*Percentage points.








+ 1.6 p.p.


+ 1.2 p.p.



Top Brands Showing Strong Growth in the U.S.

(Million USD)






27




Hispanic Population Expanding throughout the U **Genomma is Broadening its Presence**

Hispanic Population Expanding Rapidly in Non-Traditional Markets



Source: U.S. Census Bureau county population datasets / PEW Research Center.





New Clients



New E-commerce Clients



Results with Key Clients in the U.S.




Side-Kicks 2,269 stores



Agenda





LAB Highlights: Then and Now


Brand Equity Commercial Strategy Innovation

Financial Results and Outlook



Commercial Key Variables





Traditional Channel New Customers Channel Mix

Cicatricure Asepxia OTC

Shelf Displays Featuring


Trade Terms Reduction Payment Behind Performance







+27,612 New Stores*



*From March 2014 to date.

11% of Total Sales*

Channel and Customer Expansion (Global)




Botiquín Abarrotes Supporting distribution expansion

Sold as an SKU



Deployed at mom-and-pop







15,000 Independent Drug Stores in Mexico by YE 2016



Botiquín Farmacia






75% of Supermarket Stores in Mexico with Off-Shelf Visibility.



Asepxia



Zan Zusi





Cicatricure






25% of Pharmacy Chains





Asepxia & Cicatricure

Cicatricure



Department Stores











% of in-store perfect execution.







POS Execution



3


Cuernavaca

Bodega**Aurrera**

Observatorio



Supercenter Arboledas











San Pablo







laC

Fuentes del Valle





Mega Pilares







Soriana Sendero







Soriana Solidaridad

POS Execution



3

Supercenter Plaza Texcoco

Walmart >



Supercenter Tepeyac

Supercenter Lago de Guadalupe










Supercenter Toreo

Supercenter Querétaro



Agenda





LAB Highlights: Then and Now

Brand Equity Commercial Strategy Innovation

Financial Results and Outlook



Asepxia: 360 Degree Relaunch and Execution

New Formulation

New Design




Perfect balance

Technology + Natural Ingredients



Modern image, focus on functional benefits



Makeup Product Line Evolution

BB in entire makeup product line

8 benefits in one



Cream & Powder

A New Segment for SUEROX +75% SELL-OUT







NO 70160 MR 444 45 0000 URBANATLÓN SUEROX







and a state





Salandy Writes



New Global Marketing and Innovation Process





- Lead Markets
- Creative
- R&D

Category & brand strategy

Brand footprint

Communication ideas

Innovation



Two Year Innovation on Core Brands and Base Business Upgrade





Goicoechea



Antimycotic

CORE BRANDS & CATEGORIES



Asepxia



Cough & Cold

Innovation pipeline: + 90 Products for the coming years





Tío Nacho

Analgesic

Women's Health







Gastro



Agenda






LAB Highlights: Then and Now

Brand Equity Commercial Strategy Innovation


Financial Results and Outlook



3Q YTD 2016: Growth in Top Line Profitability and FCF



*Adjusted due to non-recurring severance payments.





Stronger Policies and Disclosure

- Strengthening of <u>corporate policies</u> and procedures resulted in one-off effects, primarily non-cash, in 4Q and FY 2015 results.
- **Tightened policies and procedures with additional** oversight to support future strategy.
- Smooth and incident-free SAP implementation improves transparency and controls.






BALANCE SHEET As of 3Q'16

(Million MXN)

Total Assets	18,203	18,203
Cash and equivalents	1,592	1,020 1,431
Accounts receivable	2,304	
Inventories	1,192	5,881
Other current assets	3,540	114
Fixed, intangible and other LT assets		



203

Total Liabilities + Shareholders' Equity

20 1

Suppliers Other current liabilities



Bonds and banking debt

Non-current liabilities

Shareholders' equity



Latest News: LAB Now Running on SAP S/4 HANA



* Gartner. ** Swiss Property - SAP Capital Markets.



SAP launched S/4 HANA in February 2015 (biggest technological change* in over two decades, replacing classical R/3 ERP)

1Q'16 - First worldwide S/4 HANA

implementation is announced**

3Q'16 - LAB Mexico goes live in S/4 HANA

First implementation in Latin America Not an upgrade; no disruption


LAB developed Global Template

Journey for other countries in 2017

Full benefits expected to be captured in 2017


Evolution of Net Debt

(Million MXN)




4Q12 2Q13 4Q13 2Q14 4Q14 2Q15 4Q15 2Q16 3Q16

50






Capital Allocation Concept



* Non-Gaap measure defined as Operating Cash Flow less maintenance Capex.





Higher Lower (than in 2016)

Fund Value Creation


New Projects for growth efficiency



M&A Strategy

Accretive Inorganic Growth

- Non-transformational
- Focus on big geographies, mainly Mexico and the U.S.
- Mainly OTC
- Brand heritage and growth potential
- OPEX synergy opportunities
- Focus on ROIC






COGS Reduction

New Production Capabilities Rationale

- Four last quarters intensive analysis
- Scale: filling, bottles, raw materials
- Quality
- Fill-rate
- Attracted GM's talent from the best generics and PC producers in Latam
- Mexico has one of the lowest production costs in the world
- Business model sustainability

Investment Opportunity (24 months)

- Up to MXN \$800 million
- EBITDA savings: 700 bps to 910 bps
- ROIC: > 30%



nd PC producers in Latam s in the world






Net Sales Growth (MXN):

EBITDA Growth (MXN):

FCF (billion MXN):

ROIC Objective:

Net Debt/EBITDA Target:







> \$1.8

~ 30%







INVESTOR RELATIONS CONTACT:

ANA MARÍA YBARRA – IRO **BARBARA CANO** – MBS Value Partners

inversion@genommalab.com Tel. (55) 5081-0000 ext. 4016

www.genommalab.com/inversionistas

